Novo Holding’s acquisition of Catalent is looking increasingly contentious after Roche’s CEO Thomas Schinecker added his voice to calls for regulators to block the move, saying it is anti-competitive.
Novo Hits Back As Roche CEO Joins Catalent Takeover Opposition
Breaking with convention, Thomas Schinecker has said allowing the $16.5bn acquisition to go ahead would be “the wrong decision”. Novo Nordisk says otherwise.
More from Manufacturing
• By
J&J followed in the footsteps of Lilly and Merck, which have announced multibillion-dollar investments in US manufacturing since Donald Trump’s inauguration.
• By
A joint venture with AI specialist Hologen will bring in much-needed cash for the ambitious gene therapy firm.
• By
Can India’s Mittelstand or small and medium enterprises win the quality game and what could help? Sectoral insights from defense and FMCG industries and from other countries like Germany might hold the key for Indian pharma, a panel of experts at a recent event opined.
• By
Indian CDMOs could consider collaborating with allies in Europe amid a focused effort via a new industry body to counter existing challenges like China’s manufacturing, regulatory and policy advantages and a shortage of funding and talent in the country even as talk of US tariffs throws a new spoke in the wheel
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.